Thermo Fisher Scientific (TMO) Common Equity (2009 - 2026)

Thermo Fisher Scientific has disclosed Common Equity across 18 years of filings, most recently posting $51.9 billion for Q1 2026.

• Quarterly Common Equity rose 5.22% year-over-year to $51.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.9 billion (up 5.22% YoY) and the FY2025 annual result came in at $53.4 billion, up 7.78% from the prior year.
• Common Equity retreated to $51.9 billion in Q1 2026, from $53.4 billion in the prior quarter.
• Over five years, Common Equity peaked at $53.4 billion in Q4 2025 and troughed at $41.0 billion in Q2 2022.
• A 5-year average of $46.9 billion and a median of $46.7 billion in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity gained 16.97% — and 2023, when it gained 3.15%.
• Tracing TMO's Common Equity over 5 years: stood at $44.0 billion in 2022, then climbed by 6.11% to $46.7 billion in 2023, then advanced by 6.05% to $49.6 billion in 2024, then climbed by 7.78% to $53.4 billion in 2025, then fell by 2.76% to $51.9 billion in 2026.
• Business Quant data shows TMO's Common Equity at $51.9 billion in Q1 2026, $53.4 billion in Q4 2025, and $51.0 billion in Q3 2025.